Symbols

Celcuity Inc. Soars 245.53% on Positive Clinical Trial Results

Generated by AI AgentAinvest Pre-Market Radar

Monday, Jul 28, 2025 8:15 am ET1min read

Aime Summary

- Celcuity Inc. surged 245.53% pre-market after Phase 3 VIKTORIA-1 trial showed 76% reduced disease progression risk in PIK3CA wild-type breast cancer patients.

- The 7.3-month progression-free survival gain in the cohort has positioned Celcuity as a leader in innovative breast cancer therapies.

- The company plans to submit an NDA by Q4 2025, with full data pending, potentially driving further investor confidence and market interest.

On July 28, 2025, Celcuity Inc.CELC-- experienced a remarkable surge of 245.53% in pre-market trading, driven by significant developments in its clinical trials.

Celcuity Inc. announced topline results from its Phase 3 VIKTORIA-1 trial, revealing a 76% lower risk of disease progression and a 7.3-month gain in progression-free survival (PFS) for the PIK3CA wild-type cohort. These findings are clinically meaningful and have sparked optimism among investors.

The company plans to submit a New Drug Application (NDA) in the fourth quarter of 2025, with full data to follow. This milestone is expected to further bolster investor confidence and potentially drive additional gains in the stock price.

Celcuity's breakthrough results have positioned the company as a leader in the development of innovative breast cancer treatments, attracting significant market attention and investment interest.

Ainvest Pre-Market Radar

Get the scoop on pre-market movers and shakers in the US stock market.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments

﻿

Add a public comment...

No comments yet

AInvest
PRO

Editorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process. While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context. Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue